Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Phase 2 Terminated 70 enrolled University of Chicago Northwestern University · collab Temple University · collab University of Southern Mississippi · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.

Timeline

Start: 2010-09
Primary completion: 2014-11
Completion: 2014-11

Outcome

Outcome not reported

Stopped (Enrollment): “Funding withdrawn due to inability to accrue”

Publications

Stoffers-Winterling JM, Storebo OJ, Pereira Ribeiro J, Kongerslev MT, Vollm BA, Mattivi JT, Faltinsen E, Todorovac A, Jorgensen MS, Callesen HE, Sales CP, Schaug JP, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Escitalopram	Small molecule	20 mg	—